Show simple item record

dc.contributor.authorKostandini, Gentianen
dc.contributor.authorMills, Bradford F.en
dc.date.accessioned2020-02-03T16:14:12Zen
dc.date.available2020-02-03T16:14:12Zen
dc.date.issued2005-07en
dc.identifier.urihttp://hdl.handle.net/10919/96669en
dc.description.abstractSmall firms developing biotechnology applications often focus on establishing intellectual property rights, which can then be sold to more established firms with existing market chains. This paper explores the expected ‘Buyout’ price and economic surplus changes for an emerging bio-pharming application with transgenic tobacco. The results suggest a ‘Buyout’ price of about $1.75 billion. Yet despite this potentially large payout to the innovating firm, consumers also see significant surplus gains.en
dc.format.extent27 pagesen
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.publisherVirginia Techen
dc.relation.ispartofAmerican Agricultural Economics Association Annual Meeting, 2005en
dc.rightsIn Copyright (InC)en
dc.rightsThis Item is protected by copyright and/or related rights. Some uses of this Item may be deemed fair and permitted by law even without permission from the rights holder(s). For other uses you need to obtain permission from the rights holder(s).en
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectBuyouten
dc.subjectbio-pharmingen
dc.subjecttransgenic tobaccoen
dc.subjectimperfect competitionen
dc.subjecteconomic surplusen
dc.titleMarket Strategies for a Tobacco Bio-Pharming Application: The Case of Gaucher’s Disease Treatmenten
dc.typePresentationen
dc.contributor.departmentAgricultural and Applied Economicsen
dc.type.dcmitypeTexten


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record